Thalia Therapeutics PLC THAT
LSE · United Kingdom · Health Technology
GBp 0.62500.00 (0.00%)
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Thalia Therapeutics (AIM:THAT) CEO Dr David Solomon joined Proactive's Stephen Gunnion to discuss the acquisition of Sanmirna Therapeutics and how it transforms Thalia into a clinical-stage RNA therapeutics business. The deal brings clinical-stage asset miRisten into Thalia's portfolio, adding a Phase 1 trial currently recruiting AML patients at City of Hope. miRisten targets miR-126, a microRNA associated with disease progression. Solomon explained that reducing it may slow AML while making leukaemia stem cells more susceptible to existing treatments such as Venetoclax and chemotherapy. The a
Acquisition of oncology company Sanmirna Therapeutics Inc for its clinical-stage Acute Myeloid Leukaemia RNA therapy Acquisition catapults Thalia to a clinical-stage RNA therapeutics company and is expected to be fundamentally value accretive Advances ...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.